CorePath partners with Cizzle Bio to develop blood test to detect lung cancer
Lung cancer is the leading cause of cancer death in the USA, making up almost 25% of all cancer deaths
Lung cancer is the leading cause of cancer death in the USA, making up almost 25% of all cancer deaths
This Keytruda combination is the first immunotherapy option approved in the EU for high-risk early-stage TNBC
The two-year agreement will grant Lonza access to IBF's prominent network and allow IBF to benefit from Lonza's manufacturing expertise and knowledge in its due diligence review of potential targets
Belmore, the brand name of Bempedoic acid, is a novel drug for the treatment of high LDL-cholesterol.
Successfully removed peanut from the child’s left lung through bronchoscopy
Ulcerative colitis is a chronic, immune-mediated inflammatory bowel disease that can lead to substantial burden and often disability among patients
Researchers have found out that myopia often leads to an abnormal increase in axial length. When the axial length grows to more than 25mm, especially with age, problems like cataracts or glaucoma can appear
Positive opinion could expand the role of Cosentyx (secukinumab) in reducing flare risk in pediatric enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) patients in the EU
Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of USFDA’s Priority Review action date
Key senior hire will partner with Allison Ceraso, President and CCO, bolstering agency leadership amongst continued network momentum
Subscribe To Our Newsletter & Stay Updated